Interpace Diagnostics (IDXG) Reports Q3 Loss of $0.11, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Interpace Diagnostics (IDXG) Reports Q3 Loss of $0.11, Revenues Beat

Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments

November 13, 2018 4:18 PM EST

Conference Call Tuesday, November 13, 2018 at 4:30 pm ET

PARSIPPANY, NJ,, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced financial results and business progress for the quarter ended September 30, 2018, as well as recent accomplishments.

Topline highlights include:

Expanded Guidance of Revenues for the Year to a Range between $21 and $22 MillionRevenue Grew to $5.8 Million in the Third Quarter... More